Privia Health Group (NASDAQ:PRVA) Receives “Buy” Rating from Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of Privia Health Group (NASDAQ:PRVA) in a report released on Thursday morning,Benzinga reports. They currently have a $30.00 target price on the stock.

Other equities analysts have also recently issued reports about the stock. Stephens restated an “overweight” rating and issued a $26.00 target price on shares of Privia Health Group in a research report on Thursday, January 2nd. Canaccord Genuity Group boosted their price objective on shares of Privia Health Group from $29.00 to $30.00 and gave the company a “buy” rating in a research report on Friday, February 28th. Truist Financial raised their target price on Privia Health Group from $27.00 to $28.00 and gave the company a “buy” rating in a report on Thursday. JMP Securities set a $29.00 price target on Privia Health Group in a report on Friday, February 28th. Finally, Macquarie assumed coverage on Privia Health Group in a research report on Monday, December 16th. They set an “outperform” rating and a $25.00 price objective for the company. One investment analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $26.87.

Privia Health Group Stock Performance

Shares of NASDAQ PRVA opened at $24.10 on Thursday. The stock has a market capitalization of $2.92 billion, a P/E ratio of 241.02, a PEG ratio of 3.47 and a beta of 0.88. The stock’s fifty day moving average is $23.76 and its 200 day moving average is $21.49. Privia Health Group has a 52 week low of $15.92 and a 52 week high of $26.04.

Insiders Place Their Bets

In other news, CFO David Mountcastle sold 5,630 shares of the firm’s stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $22.38, for a total transaction of $125,999.40. Following the completion of the transaction, the chief financial officer now directly owns 179,676 shares in the company, valued at $4,021,148.88. This trade represents a 3.04 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 14.20% of the company’s stock.

Institutional Trading of Privia Health Group

Institutional investors have recently added to or reduced their stakes in the stock. XTX Topco Ltd bought a new stake in shares of Privia Health Group in the 3rd quarter valued at $182,000. Barclays PLC lifted its holdings in Privia Health Group by 240.3% in the third quarter. Barclays PLC now owns 224,018 shares of the company’s stock valued at $4,079,000 after buying an additional 158,188 shares during the period. Geode Capital Management LLC boosted its position in Privia Health Group by 1.0% during the third quarter. Geode Capital Management LLC now owns 2,415,022 shares of the company’s stock valued at $43,986,000 after acquiring an additional 23,178 shares during the last quarter. Neo Ivy Capital Management acquired a new stake in Privia Health Group during the 3rd quarter worth about $66,000. Finally, Virtu Financial LLC bought a new position in shares of Privia Health Group in the 3rd quarter worth about $263,000. 94.48% of the stock is currently owned by institutional investors.

Privia Health Group Company Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.